IRS Commissioner Nominee Daniel Werfel Testifies Before Senate Finance Committee
Client Alert | 1 min read | 02.24.23
On February 15th, Daniel Werfel, the nominee for IRS Commissioner, testified before the Senate Finance Committee during his nomination hearing. As expected, Werfel faced tough questioning about how he would oversee the use of $80 billion in new funding coming to the IRS over the next decade. The Inflation Reduction Act, which passed late last year, appropriated the additional funding for the IRS to increase compliance and provide better customer service to taxpayers.
Republicans have criticized the additional funding, citing fears that the investment in the IRS will increase audits of individual and small business taxpayers. Treasury Secretary Janet Yellen addressed this concern, stating that the new funding will not be used to increase the audit rate for households making under $400,000 a year. Werfel committed during his nomination hearing to following Secretary Yellen’s directive.
Werfel testified that, if confirmed, “the audit and compliance priorities will be focused on enhancing the IRS’ capabilities to ensure that America’s highest earners comply with applicable tax laws.” As a result, we expect to see more coordinated and potentially more aggressive audits of high-earning individuals and corporations.
Werfel also testified that, if confirmed, he would focus on modernizing the IRS, improving taxpayer service, overhauling the agency’s technology systems, and adding additional IRS employees in customer service roles and with expertise in complex tax matters. The tax community has lamented the IRS’s customer service capabilities and outdated systems for years and these proposed modernization efforts are a welcome, much needed change.
We will continue to follow the IRS’s enforcement efforts as they develop and provide updates.
Insights
Client Alert | 2 min read | 05.09.25
FDA Seeks Stakeholder Consultation on Prescription Drug User Fee Reauthorization
On May 8, the U.S. Food and Drug Administration (FDA) took steps to begin the process for reauthorizing the Prescription Drug User Fee Amendments (PDUFA) by announcing a public meeting to be held on July 14, 2025. The agency invited public stakeholders, including patient and consumer advocate groups, health care professionals, and scientific and academic experts to participate in the meeting and subsequent public meetings to consult on the PDUFA reauthorization.
Client Alert | 2 min read | 05.09.25
New SF-328 for Foreign Ownership, Control, and Influence Assessments Approved, Publication Imminent
Client Alert | 4 min read | 05.08.25
Client Alert | 4 min read | 05.07.25